Loading...
•
Sep 30, 2021
Intra-Cellular Q3 2021 Earnings Report
Intra-Cellular Therapies reported a net loss of $76.9 million and total revenues of $22.2 million, with CAPLYTA net product revenues reaching $21.6 million. The company is progressing with bipolar depression launch preparations and advancing its development programs.
Key Takeaways
Intra-Cellular Therapies announced its Q3 2021 financial results, reporting a net loss of $76.9 million. Total revenues were $22.2 million, driven by CAPLYTA net product revenues of $21.6 million. The company continues to advance its development programs and prepare for the potential launch of CAPLYTA in bipolar depression.
Total revenues reached $22.2 million, a 200% increase compared to the same period last year.
CAPLYTA net product revenues were $21.6 million.
CAPLYTA total prescriptions increased 15% versus the previous quarter.
Bipolar depression launch preparations are progressing well, with sales force expansion substantially complete.
Intra-Cellular
Intra-Cellular
Forward Guidance
The company is focused on commercializing CAPLYTA, advancing its development programs, and preparing for the potential launch of CAPLYTA in bipolar depression.
Positive Outlook
- Progress in commercialization of CAPLYTA in schizophrenia.
- Advancement of development programs.
- Bipolar depression launch preparations are progressing well.
- Sales force expansion is substantially complete.
- Potential FDA approval of CAPLYTA for bipolar depression.
Challenges Ahead
- Uncertainties regarding FDA approval of sNDAs.
- Potential delays or challenges in commercializing CAPLYTA.
- Negative impact of COVID-19 pandemic on commercial plans and sales.
- Risks associated with clinical trials.
- Unexpected safety or tolerability issues with CAPLYTA.